Details of Drug-Drug Interaction
| Drug General Information (ID: DDI1LZPKRF) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Certolizumab pegol | Drug Info | Talimogene laherparepvec | Drug Info | |||||
| Drug Type | Monoclonal antibody | Vaccine | |||||||
| Therapeutic Class | Tnf Alfa Inhibitors | Anticancer Agents | |||||||
| Mechanism of Certolizumab pegol-Talimogene laherparepvec Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Certolizumab pegol | Talimogene laherparepvec | |||||||
| Mechanism | Immunosuppressive effects | Vaccine or toxoid | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Vaccine/toxoid | ||||||||
| Factor Description | The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Imlygic (talimogene laherparepvec). Amgen USA, Thousand Oaks, CA. | ||||||||||||||||||